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Abstract
In vitro data showed that immunoglobulin G (IgG) from patients with lupus nephritis (LN) could bind to cultured human
mesangial cells (HMC). The clinical relevance of such binding was unknown. Binding of IgG and subclasses was measured in
189 serial serum samples from 23 patients with Class III/IV6V LN (48 during renal flares, 141 during low level disease activity
(LLDA)). 64 patients with non-lupus glomerular diseases (NLGD) and 23 healthy individuals were used as controls. HMC-
binding was measured with cellular ELISA and expressed as OD index. HMC-binding index of total IgG was 0.1260.09,
0.3660.25, 0.5960.37 and 0.7460.42 in healthy subjects, NLGD, LN patients during LLDA, and LN flares respectively
(P= 0.046, LN flare vs. LLDA; P,0.001, for healthy controls or NLGD vs. LN during flare or LLDA). Binding of serum IgG1 to
HMC was 0.0560.05, 0.1560.11, 0.4160.38 and 0.5560.40 for the corresponding groups respectively (P= 0.007, LN flare vs.
remission; P,0.001, for healthy controls or NLGD vs. LN during flare or remission). IgG2, IgG3 and IgG4 from patients and
controls did not show significant binding to HMC. Total IgG and IgG1 HMC-binding index correlated with anti-dsDNA level
(r = 0.26 and 0.39 respectively, P,0.001 for both), and inversely with C3 (r =20.17 and 20.45, P,0.05 for both). Sensitivity/
specificity of total IgG or IgG1 binding to HMC in predicting renal flares were 81.3%/39.7% (ROC AUC 0.61, P= 0.03) and
83.8%/41.8% (AUC 0.63, P= 0.009) respectively. HMC-binding by IgG1, but not total IgG, correlated with mesangial immune
deposition in LN renal biopsies under electron microscopy. Our results showed that binding of serum total IgG and IgG1 in
LN patients correlates with disease activity. The correlation between IgG1 HMC-binding and mesangial immune deposition
suggests a potential pathogenic significance.
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Introduction
Lupus nephritis (LN) is a severe manifestation in patients with
systemic lupus erythematosus (SLE), and is an important cause of
renal failure in some racial groups such as Asians [1,2]. The
treatments to date are based on non-selective immunosuppression.
The pathogenic mechanisms are multifactorial and complex, but
increased understanding of the pathogenic mechanisms could lead
to improvements in disease activity monitoring and treatment.
SLE is a prototype autoimmune disease and is characterized by
the production of different autoantibodies, resulting in immune-
mediated injury to various organs including the kidneys [3,4]. The
pathogenic importance of anti-dsDNA antibodies is exemplified by
in vitro studies demonstrating their presence in renal eluates
obtained from patients and mice with LN [5–7], and by clinical
observations demonstrating a correlation between anti-dsDNA
antibody titre and disease activity [8].
Mesangial cells have a central location in the glomerulus. Not
only do mesangial cells provide structural support to adjacent
capillary loops but it is well established that they also participate
actively in disease mechanisms through the production of
inflammatory and fibrotic growth factors [9,10]. Immunoglobulin
deposition in the mesangial area, mesangial cell proliferation, and
increase in mesangial matrix are constant features in renal biopsies
of active LN [3,11]. Our group has previously reported that anti-
dsDNA isolated from patients with LN can bind to human
mesangial cells (HMC) and such binding correlates with clinical
activity in selected LN patients and could contribute to intra-renal
disease pathogenesis [12,13]. We also observed a correlation
between anti-dsDNA and total IgG levels. In this study, we
investigated whether the binding activity of total serum IgG and its
subclasses to HMC might have clinical correlations in patients
with LN, which have implications on the use of such binding as a




This study and the consent procedures were approved by the
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster (HKU/HA HKW
IRB). All included subjects have signed consent for the use of the
serum samples in this study and the consent forms are kept in
patients’ case records. Patients attending follow-up at the SLE
Clinic of Queen Mary Hospital, Hong Kong, with biopsy-proven
Class III/IV6V LN and two or more episodes of renal flare
during the period 2001 to 2013 were included. Histological
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findings of LN were reported in accordance with the International
Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003
classification [14,15]. Standard treatment for active LN included
corticosteroids combined with either cyclophosphamide or
mycophenolate mofetil (MMF) as induction immunosuppression,
followed by low-dose corticosteroids with either azathioprine or
MMF as long-term maintenance immunosuppression. Disease
activity was categorized as ‘‘active’’ or ‘‘low level disease activity’’
(LLDA) on the basis of both clinical and serologic parameters.
‘‘Active’’ disease had SLE Disease Activity Index (SLEDAI) score
.10 with $4 points in the renal domain, and ‘‘low level disease
activity’’ status was defined by SLEDAI score,4 with no points in
the renal domain [16]. Patients with non-lupus glomerular diseases
(NLGD) and healthy subjects (age- and sex-matched) were
included as controls. The NLGD group included patients with
IgA nephropathy, minimal change nephropathy, membranous
nephropathy and ANCA-associated glomerulonephritis, and
serum samples were obtained at presentation when the diagnoses
were established by renal biopsy.
Laboratory methods
Archived serum samples from LN patients collected at baseline
(i.e. at initiation of induction therapy) then serially at 3-month
intervals with informed consent were retrieved. Single serum
samples were obtained from patients with non-lupus glomerular
diseases and healthy subjects.
HMC-binding activity of IgG in serum samples was measured
using a cellular ELISA as previously described [12]. Briefly, HMC
were seeded into 96-well microtitre plates at a density of 10,000
cells/cm2. Cells were cultured in RPMI 1640 medium supple-
mented with 15% FCS and medium changed every 3 days. At
90% confluence HMC were growth arrested for 72 h, washed
with PBS then fixed with 1% paraformaldehyde in PBS for
15 min. Cells were washed thrice with PBS in between steps, and
all incubations were for 1 h at 37uC. HMC were blocked with 3%
BSA followed by normal IgG (100 mg/ml) to block Fc receptor-
mediated binding. HMC were incubated with serum samples
(diluted 1:100, 100 ml) in triplicate, then incubated with anti-
human IgG F(ab) conjugated with alkaline phosphatase. Degree of
IgG binding to HMC was detected by incubation with para-
nitrophenol phosphate at room temperature and with optical
density measurement at A405/420 when pre-established positive
control sample showed an optical density of 1.5. The positive
control was pooled serum from a patient with high HMC-binding
activity. Seropositivity for HMC binding was denoted by results
that exceed mean+3SD of results from healthy subjects. Circulat-
ing anti-dsDNA antibody titre was measured using a commercial
ELISA (Microplate autoimmune anti-DNA quantitative ELISA)
according to the manufacturer’s instructions (BioRad, Hong
Kong). Samples giving a value .60 IU/ml were considered
positive. Kidney biopsies were performed within one week when
renal flares were suspected clinically, and were reviewed by the
same pathologist. The amount of mesangial deposits was semi-
quantitated by electron microscopy (EM) in the following scale:
0 = no deposit; 1 = scanty deposits; 2 =moderate deposits; 3 = nu-
merous deposits.
Data analysis and statistics
Continuous variables were expressed as mean6SD and
analyzed by student’s t-test, unless otherwise specified. Categorical
variable were expressed as frequencies and percentages, and
analyzed with Chi-square test where appropriate. Correlation of
HMC-binding activity with clinical parameters was assessed by the
Spearman’s method. The sensitivity/specificity, positive and
negative predictive value (PPV and NPV) of HMC-binding
activity in predicting renal flares was calculated, and the Area
Under Curve (AUC) of the Receiver Operator Characteristics
(ROC) curves was determined. Statistical analysis was performed
by Graphpad Prism 5 (La Jolla, California, USA) and two-tailed P
values,0.05 was considered statistically significant.
Results
Patient characteristics
Twenty-three Chinese patients with biopsy-proven Class III/
IV6V LN and who had experienced at least two episodes of renal
flares during follow-up of 138.2680.5 months were included
(Table 1). A total of 276 serum samples were analyzed, with 189
samples from LN patients (48 during active renal flare and 141
during LLDA, 64 samples from patients with non-lupus glomer-
Table 1. Characteristics of 23 patients with Class III/IV6V lupus nephritis who had two or more episodes of renal flare during
follow-up and included in the present study.
Age (year) 39.4611.2
Female/Male 14/9




Mycophenolate mofetil 18 (78.3%)
Azathioprine 19 (82.6%)
Calcineurin inhibitors 8 (34.8%)
Laboratory parameters at first renal flare
Serum creatinine level (mmol/L) 111.8656.4
Urine protein (g/D) 3.163.4
Anti-dsDNA level (iu/mL) 238.76249.3
C3 level (mg/dL) 64.4638.1
doi:10.1371/journal.pone.0101987.t001
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ular diseases (NLGD), and 23 samples from healthy subjects
respectively.
HMC-binding activity of serum total IgG and its
subclasses in LN patients
Binding index of serum total IgG to HMC was 0.1260.09,
0.3660.25, 0.5960.37 and 0.7460.42 for healthy controls,
NLGD, LN patients during LLDA, and active LN respectively
(P=0.046, LN flare vs. LLDA; P,0.001, healthy controls or
NLGD vs. active or inactive LN; P,0.001, NLGD vs. active or
inactive LN) (Figure 1, A). Binding index of serum IgG1 to HMC
was 0.0560.05, 0.1560.11, 0.4160.38 and 0.5560.40 for healthy
controls, NLGD, LN patients in LLDA, and active LN respec-
tively (P=0.007, LN flare vs. LLDA; P,0.001, healthy controls or
Figure 1. Mesangial cell-binding by (A) total IgG and (B) IgG1 in serum samples of patients with inactive or active lupus nephritis,
non-lupus glomerular diseases, and patients with inactive or active lupus nephritis, non-lupus glomerular diseases, and healthy
controls.
doi:10.1371/journal.pone.0101987.g001
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Figure 2. Correlation between mesangial cell-binding by (A) total IgG and (B) IgG1 with anti-dsDNA level in 23 patients with Class
III/IV±V lupus nephritis.
doi:10.1371/journal.pone.0101987.g002
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Figure 3. Negative correlation between mesangial cell-binding by (A) total IgG and (B) IgG1 with C3 level in 23 patients with Class
III/IV±V lupus nephritis.
doi:10.1371/journal.pone.0101987.g003
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NLGD vs. active or inactive LN; P,0.001, NLGD vs. active or
inactive LN) (Figure 1, B). There was no significant binding of
serum IgG2, IgG3 or IgG4 to HMC, which also did not vary
between healthy controls, NLGD patients, and LN patients during
flare or LLDA.
HMC binding by serum IgG and IgG1 and clinical
parameters
Total serum IgG and serum IgG1 HMC-binding index both
correlated positively with anti-dsDNA levels (r = 0.26 and 0.39
respectively, P,0.001 for both) (Figure 2, A&B). In contrast, both
showed a negative correlation with C3 levels (r =20.17 and
20.45 respectively, P,0.05 for both) (Figure 3, A&B). HMC-
binding by IgG and IgG1 was not related to the level of serum
creatinine, serum albumin, or proteinuria at the time of blood
sample collection (P=0.735, 0.546 and 0.700 respectively for total
IgG HMC-binding; P=0.628, 0.443 and 0.170 for IgG1 HMC-
binding).
Overall sensitivity/specificity of total IgG or IgG1 HMC-
binding index in the prediction of renal flares (with or without
systemic flares) was 81.3%/39.7% (AUC 0.61, P=0.030) and
83.8%/41.8% (AUC 0.63, P=0.009) respectively (Figure 4,
A&B). The overall PPV and NPV of total IgG or IgG1 HMC-
binding index in prediction of renal flares (with or without
systemic flares) were 31.5%/86.2% and 32.8%/88.1% respective-
ly. The sensitivity/specificity of total IgG or IgG1 HMC-binding
index to predict renal flares with concomitant systemic flares were
80.0%/35.1% (PPV: 12.1%; NPV: 94.1%) and 83.3%/36.1%
(PPV: 12.7%; NPV: 95.1%), and 79.6%/38.6% (PPV: 28.2%;
NPV: 86.2%) and 83.3%/40.8% (PPV: 28.7%; NPV: 89.6%) for
renal flares without systemic flares. Two patients (8.7%) showed
positive total IgG and IgG1 binding to HMC during active renal
flare when their anti-dsDNA and C3 levels remained within
normal limits. Seropositivity of HMC-binding IgG1 precedes renal
flares by 43.8662.9 days.
HMC binding by serum IgG and IgG1 and mesangial
immune deposition assessed by electron microscopy
Total IgG HMC-binding seropositivity was not related to the
degree of mesangial immune deposition (P=0.733). In contrast,
patients seropositive for IgG1 HMC-binding were more likely to
show increased mesangial immune deposition at grades 2 or 3 (i.e.
moderate to numerous) (P=0.016). HMC-binding index of IgG1,
but not total IgG, also correlated positively with the mesangial
deposition score (r = 0.776 and P,0.001 for IgG1; r = 0.263 and
P=0.363 for total IgG).
Discussion
SLE is characterized by the production of various autoantibod-
ies [4]. Previous studies have reported that different autoantibodies
can bind to different renal components including podocytes,
mesangial cells, endothelial cells, and renal tubular epithelial cells,
and it has been speculated that such binding could have a
pathogenic role in immune-mediated kidney injury [10,12,13,17–
19]. Mesangial cells are located strategically at the centre of
glomeruli and are juxtaposed to the capillary loops [9]. Mesangial
immunoglobulin deposition and mesangial cell proliferation are
cardinal histological features in LN [3,11]. Our previous
investigations showed that anti-dsDNA antibodies from patients
with LN could bind to HMC and trigger cellular responses
involved in inflammation and fibrosis, and that such binding
correlated with total serum IgG level (10,12). The present study
sought to investigate the potential clinical correlations of the in
vitro findings.
Our results showed a clear relationship between disease activity
and HMC-binding by total serum IgG and IgG1 in LN, and the
degree of binding was significantly increased in LN compared with
healthy subjects and patients with non-lupus glomerular diseases.
Also, the positive correlation of IgG HMC-binding with anti-
dsDNA level, and negative relationship with C3 level, prompted us
to investigate whether HMC-binding index might serve as a
biomarker for disease activity monitoring. In this context, previous
studies have also found that active LN patients had significantly
stronger IgG binding to isolated rat glomeruli in an in vitro assay
when compared to SLE patients without nephritis [20]. That
HMC-binding index of total IgG or IgG1 was not related to serum
creatinine, serum albumin, or proteinuria was not a disadvantage
since these clinical parameters represent a summative outcome of
both active disease and prior chronic damage and are also subject
to modulating factors distinct from the lupus disease process such
as hypertensive renal damage. Conventional serological parame-
ters C3 and anti-dsDNA levels have been reported to show
sensitivity and specificity of 49–79% and 51–74% respectively in
the detection of disease flares [21–27]. The present results from
samples collected serially in LN patients showed that in the
majority of cases increased HMC-binding by IgG and IgG1 was
associated with increased disease activity, so that these parameters
had sensitivities of over 80% in the predication of renal flares.
However, seropositivity for HMC-binding by itself could be
present in patients during remission and thus was non-specific for
active disease. Notwithstanding its lack of specificity, assessment of
HMC-binding index may be of value in the small proportion of
patients in whom conventional serological parameters such as anti-
DNA and C3 levels do not correlate with disease activity, as was
demonstrated in two of the 23 patients studied, when both anti-
DNA and C3 were still within the normal range at disease flare but
serum HMC-binding IgG was positive.
The present results also have implications on pathogenic
mechanisms in LN. Among the different IgG subclasses from
LN patients tested, only IgG1 showed significant binding to HMC.
Furthermore, HMC-binding by IgG1 correlated with clinical
disease activity and also the degree of mesangial immune
deposition as assessed by electron microscopy. In this context,
previous studies have suggested that IgG1 might be more
pathogenic compared with other IgG subclasses in LN, attributed
to its ability to fix complements [28,29]. Further studies are
required to investigate the downstream cellular processes that
follow the binding of HMC by IgG1, and whether intervention or
interruption of such binding could present a novel therapeutic
approach.
Conclusions
The degree of mesangial cell binding by circulating IgG and
IgG1 in serum samples of patients with LN correlates with disease
activity, and thus may complement anti-dsDNA and C3 as
biomarkers for disease monitoring. Its relationship with mesangial
immunoglobulin deposition in LN kidney tissue also suggests a
pathogenic role.
Figure 4. Receiver Operator Characteristics (ROC) curve for sensitivity/specificity in renal flare prediction using the level of
mesangial cell-binding by (A) total IgG and (B) IgG1 in serum samples of 23 patients with Class III/IV±V lupus nephritis.
doi:10.1371/journal.pone.0101987.g004
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